Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System

News provided by

Companion Medical

14 Dec, 2017, 07:29 ET

SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Companion Medical, a leader in the development of advanced technology to improve diabetes care, announced today that it has begun commercial sales of the InPen® system in the United States.  InPen is available by prescription only and is a covered benefit under many insurance plans.  The InPen is for use with U-100 Lilly Humalog® and Novo Nordisk Novolog® rapid-acting insulin and indicated for persons aged 12 years and older.

Continue Reading
InPen is similar in size and shape to a traditional insulin pen. It comes in 3 colors to help avoid drug confusion.
InPen is similar in size and shape to a traditional insulin pen. It comes in 3 colors to help avoid drug confusion.
The Companion App home screen gives a summary of your current data. It provides last dose and last blood glucose information, an active insulin display (like an insulin pump) and a graphical depiction of the last 10 hours. In addition, you can access the dose calculator to help with the diffcult calculations required for insulin dosing.
The Companion App home screen gives a summary of your current data. It provides last dose and last blood glucose information, an active insulin display (like an insulin pump) and a graphical depiction of the last 10 hours. In addition, you can access the dose calculator to help with the diffcult calculations required for insulin dosing.

"I am pleased to announce the commercial launch of InPen.  The InPen system is a significant step toward true integrated diabetes management," said CEO Sean Saint.  "Our team has worked diligently to develop a solution for people living with diabetes who want the benefits of an insulin pump without the cost or burden of being tethered to a device."

InPen is the first and only FDA-cleared solution that combines an insulin injector pen with an intuitive smartphone app and bolus advisor using Bluetooth® technology.  InPen tracks insulin doses, including priming, and automatically sends the data to the user's mobile device, providing decision support for the constant monitoring and calculating necessary for successful insulin therapy.  InPen includes technology to:

  • Calculate and recommend optimal dosing;
  • Track history and timing of doses for a full year;
  • Monitor insulin temperature;
  • Remind the user when to take insulin;
  • Display last dose and insulin-on-board; and
  • Generate actionable reports for the healthcare provider.

The InPen app is compatible with iOS 10 and later and is available on the Apple Store.  The app for Android is under development with expected release in Q2 2018.  The InPen app allows glucose data from blood glucose meters and continuous glucose monitors to integrate with the app via integration with Apple Health.

For more information, visit www.companionmedical.com.

About Companion Medical

Companion Medical, Inc. (www.companionmedical.com) is a privately held company based in San Diego, CA.  The company leverages cross-functional engineering expertise, clinical experience, and first-hand knowledge of diabetes lifestyles to develop innovative solutions for diabetes management.

Sean Saint
[email protected] 
858-522-0252

SOURCE Companion Medical

Related Links

http://www.companionmedical.com

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.